All
AbobotulinumtoxinA for oily forehead
October 9th 2020Dr. Katarina Kesty, St. Petersburg Skin and Laser, St. Petersburg, Fla., discusses her presentation at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting about her research using abobotulinumtoxinA injections to combat oil on the forehead.
Weekly Roundup: September 21-25
September 25th 2020ICYMI, some of the content featured this week includes articles about how to choose a telemedicine vendor, the launch of an international COVID-19 dermatology registry, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, plus more.
AAD, NPF guidelines urge liver disease monitoring in psoriasis patients
September 25th 2020The latest guidelines for psoriasis from the American Academy of Dermatology and the National Psoriasis Foundation recommend physicians monitor their patients for liver disease when prescribed medication for psoriasis, such as methotrexate.
Cross-specialty collaboration key to tracking COVID-19 skin symptoms
September 24th 2020Esther Freeman, M.D., details the team effort made by the American Academy of Dermatology’s (AAD) COVID-19 Task Force to launch an international registry documenting skin manifestations in patients diagnosed with or suspected of COVID-19 infection.
How to choose a telemedicine vendor
September 22nd 2020With the increase in telemedicine use, physicians can (virtually) meet their patients’ needs now more than ever. However, with this swift increase in telehealth usage, how can physicians choose the best telemedicine vendor for their practice with so many options available?
FDA, EMA accepts marketing applications for bimekizumab in psoriasis
September 22nd 2020UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.